ADC Linker

β-D-tetraacetylgalactopyranoside-PEG1-N3 serves as a cleavable linker in PROTAC (proteolysis-targeting chimera) research, facilitating the synthesis of antibody-drug conjugates (ADCs). This compound features an azide group that allows for click chemistry applications, including copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules. Additionally, it is capable of undergoing strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with partners containing DBCO or BCN moieties, making it a versatile tool for bioconjugation and targeted drug delivery studies.

Me-Tet-PEG4-COOH is an ADC linker featuring four polyethylene glycol (PEG) units, designed for effective conjugation in antibody-drug conjugate (ADC) applications. Its unique tetrazine group facilitates specific inverse electron demand Diels-Alder (iEDDA) reactions with trans-cyclooctene (TCO) derivatives, enabling precise and efficient targeting of therapeutic agents. This linker enhances the stability and solubility of ADCs, making it a valuable tool in cancer research and therapeutic development.

PPA is a specialized linker utilized in the formation of antibody-drug conjugates (ADCs), functioning primarily by facilitating the attachment of cytotoxic drugs to antibodies. This compound plays a crucial role in enhancing the therapeutic efficacy of ADCs by ensuring targeted delivery of the drug to cancer cells. PPA is essential for researchers developing novel ADCs aimed at improving treatment outcomes in oncology.

Bis-Tos-(2-hydroxyethyl disulfide) is a cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the selective release of therapeutic agents upon cellular uptake, enhancing the efficacy of targeted cancer therapies. Its bioactive properties make it suitable for various research applications in the development of ADCs, allowing for precise drug delivery and improved patient outcomes in oncology studies.

m-PEG8-MS is a polyethylene glycol (PEG)-based linker designed for use in antibody-drug conjugates (ADCs) and proteolysis-targeting chimeras (PROTACs). This cleavable linker facilitates the effective synthesis of ADCs, enhancing drug delivery specificity and potency. Its versatile applications in chemical biology allow for targeted degradation of selected proteins, making it a valuable tool in therapeutic development and research.

PDdEC-NB is a disulfide-cleavable linker designed for use in antibody-drug conjugates (ADCs). This reagent facilitates targeted drug delivery by enabling the selective release of cytotoxic agents in the presence of reducing conditions, thus enhancing therapeutic efficacy. It is suitable for applications in ADC development and optimization, contributing to improved specificity and reduced off-target effects in cancer therapeutics.

3,4-Dibromo-Mal-PEG4-Acid is a site-specific linker designed for antibody-drug conjugates (ADCs), featuring a dibromomaleimide moiety that enables dual substitution via its two bromine atoms. The carboxylic acid group can react with primary amines in the presence of coupling agents such as EDC and HATU, facilitating the formation of stable amide bonds. Additionally, the hydrophilic PEG4 linker enhances the solubility of the resulting conjugate in aqueous environments, making it suitable for various bioconjugation applications in chemical and biological research.

Boc-Gly-Gly-Gly-Gly-Gly is an antibody-drug conjugate (ADC) linker featuring a tert-butoxycarbonyl (Boc) protecting group on the N-terminus. The Boc group allows for selective deprotection under mild acidic conditions, yielding a free amine that can facilitate conjugation with various cytotoxic agents. This compound is instrumental in ADC development, enhancing the specificity and efficacy of targeted cancer therapies.

SNPB-sulfo-Me is a cleavable linker designed for the formulation of antibody-drug conjugates (ADCs). It facilitates the selective release of therapeutic agents upon internalization, enhancing the efficacy of targeted cancer therapies. This linker can be utilized in various research applications aimed at developing and optimizing ADCs for improved therapeutic outcomes.

NO2-SPP is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the effective attachment of cytotoxic agents to antibodies, ensuring precise delivery to target cells. Its utility in ADC development makes it a valuable tool for researchers in the fields of cancer therapeutics and bioconjugation technology.

Cbz-Phe-(Alloc)Lys-PAB-PNP is a cleavable linker designed for use in antibody-drug conjugates (ADCs). This compound facilitates the selective release of cytotoxic agents upon internalization by target cells, enhancing the therapeutic efficacy of ADCs. Its unique structure supports the effective conjugation of antibodies with drugs, making it suitable for applications in cancer research and targeted therapy development.

m-PEG6-SS-PEG6-methyl is a cleavable linker designed for use in antibody-drug conjugates (ADCs), consisting of a 12-unit polyethylene glycol (PEG) chain. This compound features a disulfide bond that enables controlled release of the drug payload in a reducing environment, enhancing the therapeutic efficacy of ADCs. It is ideal for research applications involving targeted cancer therapies and bioconjugation techniques.

Sulfo-SMPB sodium is a heterobifunctional ADC linker designed for covalent conjugation via its N-hydroxysuccinimide (NHS) ester and maleimide functional groups. This non-cleavable cross-linking reagent facilitates the attachment of amine- and sulfhydryl-containing biomolecules, making it valuable in the development of antibody-drug conjugates (ADCs) and other bioconjugation applications. Its properties enable precise targeting and enhance the stability of conjugated products in biological systems.

Propargyl-PEG1-SS-PEG1-C2-Boc is a versatile alkyl/ether-based linker with applications in PROTAC and antibody-drug conjugate (ADC) synthesis. This cleavable linker features an alkyne group, enabling its use in click chemistry via copper-catalyzed azide-alkyne cycloaddition (CuAAc). Propargyl-PEG1-SS-PEG1-C2-Boc is instrumental in the development of targeted therapeutic strategies, making it valuable for researchers in drug design and bioconjugation studies.

5-Maleimidovaleric acid is a cleavable linker specifically designed for use in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the stable attachment of drugs to antibodies while allowing for selective release of the therapeutic agent in targeted cells. Its application is critical in the development of advanced ADCs for targeted cancer therapy, enhancing therapeutic efficacy and reducing off-target effects.

MC-GGFG-NH-CH2-O-propionic acid is an antibody-drug conjugate (ADC) linker that facilitates the targeted delivery of therapeutic agents. This reagent plays a crucial role in the synthesis of ADCs, enhancing the effectiveness of cancer treatments by linking cytotoxic drugs to antibodies. Its applications extend to the development of novel bioconjugates for precise tumor targeting in research settings.

Fmoc-PEG3-Ala-Ala-Asn(Trt)-PAB is a cleavable three-unit polyethylene glycol (PEG) linker designed for the synthesis of antibody-drug conjugates (ADCs). This linker enhances the solubility and stability of the conjugate while facilitating targeted delivery of cytotoxic agents. It is suitable for research applications focused on developing ADCs for therapeutic use in oncology and other diseases.

Boc-VC-PAB-MMAF is a cleavable linker designed for the construction of antibody-drug conjugates (ADCs). This compound facilitates targeted delivery of cytotoxic agents to tumor cells, providing insights into the efficacy and mechanisms of cancer treatment. It is particularly useful in cancer research, enabling the development of innovative therapeutic strategies that enhance selective tumor targeting while minimizing systemic toxicity.

Tr-PEG8-OH is a non-cleavable linker composed of an 8 unit polyethylene glycol (PEG) chain, primarily utilized in the synthesis of PROTACs (proteolysis-targeting chimeras) and antibody-drug conjugates (ADCs). This PEG-based linker facilitates the development of optimized bioconjugates, enhancing their pharmacokinetic profiles and therapeutic efficacy. Tr-PEG8-OH is particularly valuable for research applications focusing on targeted protein degradation and drug delivery systems.

NH2-PEG4-GGFG-NH-CH2-O-CH2COOH is an amino-functionalized polyethylene glycol (PEG) linker designed for Antibody-Drug Conjugate (ADC) synthesis. This compound facilitates the formation of stable covalent bonds between antibodies and cytotoxic agents, enhancing targeted delivery and therapeutic efficacy. It is essential for research applications focused on developing and optimizing ADCs for cancer treatment and other diseases.

Sulfo-DMAC-SPP is a cleavable linker specifically designed for the construction of antibody-drug conjugates (ADCs). This reagent facilitates the selective attachment of cytotoxic agents to antibodies, thereby enhancing targeted delivery and efficacy in cancer therapy. Its incorporation into ADCs can improve therapeutic profiles by allowing controlled release of the drug within the tumor microenvironment, making it valuable for advancing research in targeted cancer treatments.

NH2-PEG4-GGFG-CH2-O-CH2-Cbz is a versatile linker specifically designed for the synthesis of Antibody-Drug Conjugates (ADCs). This compound facilitates efficient attachment of cytotoxic agents to antibodies, enabling targeted delivery for cancer therapy. Its unique structure promotes stability and optimal release profiles, making it suitable for research applications in drug development and formulation studies.

Propargyl-PEG4-thiol is a PEG-based linker specifically designed for use in the synthesis of PROTACs and non-cleavable antibody-drug conjugates (ADCs). This compound features an alkyne functional group that participates in copper-catalyzed azide-alkyne cycloaddition (CuAAc), facilitating precise conjugation with azide-containing molecules. Propargyl-PEG4-thiol is essential for advancing research in targeted protein degradation and therapeutic antibody development.

THP-PEG6-OH is a PEG-based linker designed for use in the synthesis of PROTACs (proteolysis-targeting chimeras) and non-cleavable antibody-drug conjugates (ADCs). This versatile linker, consisting of three ethylene glycol units, facilitates the conjugation of small molecules to targeting ligands. THP-PEG6-OH enables effective modulation of protein degradation pathways and enhances the therapeutic potential of ADCs in various biological research applications.

Mal-Sulfo-DBCO is a cleavable linker designed for use in antibody-drug conjugate (ADC) synthesis. Featuring a DBCO moiety, it facilitates the efficient strain-promoted alkyne-azide cycloaddition (SPAAC) reaction with azide-containing compounds. This property makes Mal-Sulfo-DBCO valuable for precise conjugation in targeted drug delivery applications, enhancing therapeutic efficacy while minimizing off-target effects.

Ala-Ala-Ala-NH-CH2OCH2COOH is an antibody-drug conjugate (ADC) linker that functions as an intermediate in ADC synthesis. This compound facilitates the conjugation of cytotoxic drugs to antibodies, enhancing the selectivity and efficacy of targeted cancer therapies. Its structure promotes stability and efficacy in various biological applications, making it a valuable tool in drug development and research.

4-DTM-phenoxy-PEG3-CH2COOH is a cleavable PEG-based linker specifically designed for antibody-drug conjugate (ADC) applications. This compound facilitates the attachment of therapeutic agents to antibodies, enhancing targeted delivery to cancer cells. Its chemical design allows for effective drug release upon internalization, making it a valuable tool for cancer research and therapeutic development.

Bis-(PEG6-acid)-SS is a cleavable linker designed for use in antibody-drug conjugates (ADCs), targeting the efficient delivery of cytotoxic agents to cancer cells. This 6 unit polyethylene glycol (PEG) moiety enhances solubility and stability while facilitating the controlled release of the attached drug through enzyme-mediated cleavage. It is an essential reagent for researchers developing optimized ADC therapies in cancer research and drug development.

Azide-PEG12-Val-Arg-PAB serves as an ADC linker, facilitating the conjugation of antibody-drug pairs. It is characterized by its unique valine-arginine scaffold, enhancing the stability and effectiveness of antibody-drug conjugates (ADCs). This compound is essential for the development and optimization of therapeutic ADC formulations in cancer research and targeted therapy.

DMAC-SPP is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). It facilitates targeted delivery of cytotoxic agents to cancer cells by releasing the drug in response to specific intracellular conditions. This reagent is essential for enhancing the efficacy and selectivity of ADCs in therapeutic applications, contributing to advancements in cancer treatment research.

m-PEG7-MS is a polyethylene glycol (PEG)-based linker designed for use in the synthesis of PROTACs and antibody-drug conjugates (ADCs). This cleavable linker facilitates the development of targeted therapeutics by enabling controlled release of active compounds. Its versatile application supports research in targeted protein degradation and drug delivery systems, making it an essential reagent for advancing science in cancer therapy and other diseases.

Fmoc-Gly-Gly-Phe-OtBu is a cleavable linker that facilitates the formation of antibody-drug conjugates (ADCs). This reagent provides a stable connection between antibodies and cytotoxic drugs, enabling targeted delivery to cancer cells. Its design enhances the therapeutic efficacy of ADCs while minimizing off-target effects, making it a valuable tool in the development of novel cancer therapies.

DBCO-NHCO-PEG4-NHS ester is a versatile linker designed for use in the synthesis of PROTACs and antibody-drug conjugates (ADCs). This PEG/alkyl/ether-based compound features a DBCO moiety that facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. Its cleavable nature enhances the functionality and targeting capabilities of therapeutic agents, making it essential for researchers involved in drug development and bioconjugation applications.

Mal-Amide-PEG4-Val-Cit-PAB-PNP is a cleavable linker designed for the development of antibody-drug conjugates (ADCs). This compound facilitates the selective delivery of cytotoxic agents to target cells by linking drugs to antibodies through a stable, yet cleavable, bond. Its specific mechanism allows for the release of the drug within the target environment, enhancing therapeutic efficacy while minimizing systemic toxicity. This linker is ideal for applications in cancer research and therapeutic development.

Azide-PEG1-Val-Cit-PABC-OH is a cleavable linker designed for use in antibody-drug conjugates (ADCs). This reagent incorporates an azide functional group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with alkyne-containing molecules. Its key application lies in the synthesis of ADCs, facilitating the precise attachment of drug components to antibodies for targeted therapy.

DBCO-PEG1-OH is an ADC linker designed for effective conjugation in antibody-drug conjugate (ADC) applications. This compound facilitates the synthesis of ADCs by providing a stable and efficient link between monoclonal antibodies and therapeutic agents. Its utility in ADC development supports research in targeted cancer therapies and drug delivery systems.

Azido-PEG3-Val-Cit-PAB-OH is a cleavable antibody-drug conjugate (ADC) linker designed for targeted therapeutic applications. Featuring an azide functional group, it facilitates bioconjugation using copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing compounds, as well as strain-promoted alkyne-azide cycloaddition (SPAAC) with DBCO or BCN moieties. This versatile linker plays a crucial role in the development of ADCs, enhancing their efficacy and therapeutic index in cancer research and treatment.

NHPI-PEG4-C2-Pfp ester is a versatile linker designed for antibody-drug conjugates (ADCs). Its primary mechanism involves facilitating the precise attachment of cytotoxic agents to antibodies, enhancing the efficacy of targeted cancer therapies. This compound is instrumental in streamlining the synthesis of ADCs, thereby advancing research in therapeutic applications and improving treatment precision in oncology.

N-Boc-N-bis(PEG4-OH) is a PEG-based linker designed for use in PROTAC (proteolysis-targeting chimera) synthesis. This cleavable linker also serves as a versatile component for the development of antibody-drug conjugates (ADCs). Due to its unique structure, it facilitates targeted drug delivery and enhances the efficacy of therapeutic agents in various biological applications.

Cyclooctyne-O-amido-PEG3-PFP ester is a non-cleavable linker designed for antibody-drug conjugate (ADC) synthesis. Utilizing click chemistry, this reagent contains an alkyne group that facilitates copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. It's ideal for researchers developing targeted therapeutics, enabling precise conjugation with reduced off-target effects.

Azido-PEG5-Ala-Ala-Asn-PAB is a cleavable linker designed for use in antibody-drug conjugates (ADCs). This 5 unit PEG-based reagent features an azide group that enables its application in click chemistry, specifically through copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing compounds. It is also suitable for strain-promoted azide-alkyne cycloaddition (SPAAC) reactions with DBCO or BCN functionalized molecules, facilitating efficient conjugation in the development of targeted therapeutics.

HX20111 is a versatile ADC linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the stable attachment of therapeutic agents to antibodies, enhancing targeted delivery and efficacy in cancer treatment. Its utilization in ADC development can contribute to improved selectivity and reduced systemic toxicity in research applications.

Bis-PEG7-acid is a polyethylene glycol (PEG) based linker specifically designed for use in the synthesis of PROTACs (proteolysis-targeting chimeras). This compound enhances the solubility and stability of the PROTAC molecules, facilitating targeted protein degradation. Its application in chemical biology supports research focused on developing novel therapeutics through targeted ubiquitination pathways.

Mal-amido-PEG3-C1-PFP ester serves as a non-cleavable linker for antibody-drug conjugates (ADCs), characterized by a three-unit polyethylene glycol (PEG) structure. This reagent enhances the solubility and stability of ADCs, facilitating improved pharmacokinetics and biodistribution. Its application in the development of targeted therapies allows for effective delivery of cytotoxic agents to specific cancer cells while minimizing off-target effects.

Ald-Ph-amido-PEG2-C2-Pfp ester is a non-cleavable PEG linker designed specifically for antibody-drug conjugates (ADCs). This 2-unit polyethylene glycol (PEG) linker facilitates efficient conjugation between antibodies and therapeutic agents, enhancing the stability and bioavailability of the conjugated compound. Its application in ADCs allows for targeted delivery of cytotoxic agents, thereby improving therapeutic efficacy while minimizing systemic toxicity.

Me-Tet-PEG9-COOH is an ADC linker featuring a tetrazine motif for targeted conjugation. This compound facilitates a specific inverse electron demand Diels-Alder (iEDDA) reaction with trans-cyclooctene (TCO) moieties, enabling efficient bioconjugation applications. Its hydrophilic PEG spacer enhances solubility and stability, making it suitable for antibody-drug conjugate research and development, particularly in targeted therapy strategies.

Fmoc-N-methyl-PEG3-CH2CH2COOH is a PEG-based cleavable linker utilized in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the effective transport of drug payloads to target cells, enhancing therapeutic efficacy while minimizing off-target effects. Additionally, it serves as a versatile linker in the development of PROTACs (proteolysis-targeting chimeras), supporting research in targeted protein degradation and drug discovery applications.

Propargyl-O-C1-amido-PEG2-C2-NHS ester is a non-cleavable linker designed for antibody-drug conjugates (ADCs) that facilitates precise molecular attachment. This 2-unit PEG linker incorporates an alkyne group, enabling the copper-catalyzed azide-alkyne cycloaddition (CuAAC) with azide-containing compounds. Its unique structure supports enhanced stability and bioactivity in various biochemical applications, making it a valuable reagent for research in targeted therapeutics and drug delivery systems.

N3-PEG3-C2-PFP ester is a non-cleavable 3-unit PEG linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound features an azide functionality, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition reactions (CuAAc) with alkyne-containing molecules. Additionally, it can engage in strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with DBCO or BCN modified compounds. N3-PEG3-C2-PFP ester is a versatile tool for enhancing the stability and efficacy of ADCs in therapeutic research applications.

Ald-Ph-amido-PEG1-C2-NHS ester is a non-cleavable polyethylene glycol (PEG) linker designed for antibody-drug conjugation (ADC) applications. This 1-unit PEG derivative facilitates the stable attachment of drugs to antibodies, enhancing the therapeutic efficacy and specificity of conjugates. Its robust chemical properties make it suitable for a variety of research applications in the development of targeted therapies.